Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Immunovant, Inc. (IMVT)

Immunovant reports Q1 net loss of $153.2 million, up from $120.6 million a year earlier

Negative Impact 3 of 5 earnings Written later

Immunovant reported a fiscal first-quarter net loss of $153.2 million, or $0.75 per share, for the quarter ended June 30, 2026, up from $120.6 million, or $0.71 per share, a year earlier. The company reported no revenue in the filing, and its cash and cash equivalents fell to $797.8 million from $902.1 million at March 31, 2026, which it says provides runway to the potential commercial launch of IMVT-1402 in Graves' disease.

Key points

  • Net loss was $153.2 million ($0.75 per share) versus $120.6 million ($0.71 per share) a year earlier.
  • Research and development expenses rose to $142.6 million from $101.2 million, mainly from IMVT-1402 clinical trial activity, including contract manufacturing costs.
  • General and administrative expenses fell to $17.7 million from $26.0 million.
  • Cash and cash equivalents were $797.8 million as of June 30, 2026, compared with $902.1 million as of March 31, 2026.

The filing

CompanyImmunovant, Inc. (IMVT)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:15 AM ET
Accession number0001764013-26-000100

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.